Utah Medical Products, Inc. (UTMD)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$72.42+3.43%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · UTMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.1% |
| Our one-year growth estimate | diamond | -6.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to long-term interest rates.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 9.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 11 industry peers · Company calendar date is not available
UTMD — dividend update
Dated 2026-11-03
OTHER EVENTS On November 3, 2026, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. A dividend of $.315 per share is payable on January 5, 2027 to shareholders of record at the close of business on December 17, 2026. A copy of the press release is attached hereto as Exhibit 99.1
Why it matters: This tests whether new biopharma, China, and Orion sales can help replace lost customers. Sales fell 12.1% in the first nine months.
Watch forFull-year sales fall 10–13% year over year, or less, while new biopharma and China sales grow from current levels.
Also watch forFull-year sales fall more than 13% year over year, or new replacement sales stay flat or decline.
Why it matters: A trial could add legal costs beyond the current year. Management said two cases in remaining courts may go to trial in 2027.
Worry ifEither remaining case is set for trial in 2027. Or UTMD reports 2027 litigation costs above its 2026 full-year estimate of $1.6 million.
Less concerning ifBoth cases are dismissed or settled before trial. Reported 2027 litigation costs stay below $1.6 million.
Why it matters: Filshie sales fell 32.7% in 3Q 2026. A lasting drop would add to pressure from lost customers and lower device sales.
Worry ifWorldwide Filshie sales fall more than 32.7% year over year in a later comparable quarter.
Less concerning ifWorldwide Filshie sales are flat or higher year over year in a later comparable quarter.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$89 on $10,000 · ±0.9% | How much price usually moves either way. |
| Bad day | $237 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,324 loss on $10,000 · 13.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.